NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations of federal securities laws.

On May 27, 2025, the company announced that the FDA issued a Refusal to File letter for its Biologics License Application for Molbreevi, its lead drug candidate for autoimmune PAP. Savara said the FDA found the submission "not sufficiently complete" for review, citing issues with the CMC section of the application. The company was unable to specify what data was missing, or why the deficiencies weren't addressed prior to submission.

Following this news, shares of Savara fell over 30% in intraday trading on the same day. To obtain additional information, go to:

https://zlk.com/pslra-1/savara-inc-lawsuit-submission-form?prid=150626&wire=1&utm_campaign=41

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/

SOURCE: Levi & Korsinsky, LLP

View the original press release on ACCESS Newswire